Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss
Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss
Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss
Shionogi to acquire IntraBio in deal worth $2bn
The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Alexion and Aide Health launch app for people with rare diseases
More than 3.5 million people in the UK live with a rare condition
CPHI Pharma Awards 2026 winners announced in Milan
The annual awards recognise excellence across 15 categories spanning innovation, manufacturing, sustainability and leadership
Latest content
Avalere Health appoints Wendy Jory as Senior Vice President, Market Access
Jory was most recently Medicine Commercialization Lead, Product and Portfolio Strategy at GSK
Read More
Beam Therapeutics appoints Eric Foster as Chief Commercial Officer
Foster previously held senior roles at Ardelyx, Amgen, Horizon and GlaxoSmithKline
Read More
Nuclera appoints Carl Raimond as CEO
Co-founder and former CEO Michael Chen transitions to Chief Scientific and Business Officer
Read More
Inizio Evoke appoints Barbara Patchefsky as Global Client Lead
Patchefsky most recently served as Global Client Director at Havas Health & You
Read More
Intelligence
The impact of AI and digital health on chronic diseases
Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, but what impact is this having on the pharma industry?
Read More
Regulatory complexity: the challenges of navigating the new normal
How functional service provider models are helping pharma adapt to regulatory uncertainty
Read More
From ambition to action: realising the true value of health
Why industry needs to engage earlier, explain value more clearly, understand service pressures and take shared responsibility for implementation
Read More
Strengthening engagement with HCPs needs deep understanding not digital bombardment
Closing the critical gap between HCPs’ need for information and the pharma industry’s ability to deliver relevant, tailored content
Read More
Cell and gene therapies – moving from niche innovations towards broader clinical use
Looking at the regulatory challenges of cell and gene therapies for serious or life-threatening rare diseases
Read More
Creating a strong patent portfolio through constant communication
Why patenting should not stop at the drug candidate stage – and why coordination between researchers and attorneys is essential for strong protection
Read More
Blogs
Latest
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy
October 14, 2026 | Genesis Research Group|HEOR, Market Access, Orphan Drugs, Payers, access and pricing, payer engagement, payer research, rpr
In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new …
What 90 Minutes of Live AI Case Practice Revealed About Physician Readiness
October 12, 2026 | Medscape Education|
At EHA 2026 in Stockholm, 425 hematologists and oncologists attended an independent, 90-minute Medscape symposium on the practical and ethical use of AI. The format …
On GLOBE Final Rule
October 9, 2026 | Genesis Research Group|GLOBE, HEOR, Market Access, Pricing, mfn
The publication of the GLOBE Final Rule provides important clarity on the administration’s approach to MFN pricing and what it could mean for pharmaceutical pricing, …
Rethinking Prenatal Migraine Management: The Clinical Case for Neuromodulation
October 8, 2026 | Medscape Education|
Disclaimer: Management of migraine in pregnancy typically combines lifestyle strategies, nonpharmacologic approaches, selected pharmacologic options when benefits outweigh risks, and, increasingly, noninvasive neuromodulation technologies.
Advancing the Frontier of Cancer Care: Medscape’s Mission at ESMO 2026
October 5, 2026 | Medscape Education|
For more than 30 years, Medscape Education’s dedication has been centered on a single goal: building independent, accredited oncology education that improves patient outcomes. This …
Your AI pilot works. That’s the problem.
October 14, 2026 | 11 London|Data Strategy
What breaks when you scale it won’t be the model. It’ll be your data.
“We’ve been told we can’t touch AI”
October 14, 2026 | 11 London|
It’s not been a great few weeks for anyone trying to make the calm, sensible case for AI tools. Researchers have been quitting the big …
Pharma leadership strategies for talent, AI adoption, and continuous learning
October 8, 2026 | Inizio|AI, Digital, Pharma, healthcare
In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to …
Invited, but not equipped: patient involvement needs more than an open door
October 8, 2026 | Cuttsy + Cuttsy|EU HTA, Joint Clinical Assessment, Joint Scientific Assessment, clinical trials
Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.
The outcomes are already chosen. So when can patients really shape them?
September 29, 2026 | Cuttsy + Cuttsy|Clinical assessment, EU HTA, Joint Clinical Assessment, Joint Scientific Consultation, clinical trial
Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.